Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)
A Randomized, Double-blind Study of Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease
- Fimasartan will be more beneficial in stabilizing the plaque vulnerability compared to control group in deferred coronary lesions.
- Fimasartan will be more beneficial in reducing total plaque volume compared to control group in deferred coronary lesions.
- Fimasartan will be more beneficial in reducing functional impairment of stenotic lesions (assessed by FFR:Fractional Flow Reserve) in deferred coronary lesions.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Gwangju, Korea, Republic of, 501-757
- Chonnam National University Hospital
-
Seoul, Korea, Republic of, 138-736
- Asan Medical Center
-
Ulsan, Korea, Republic of, 682-714
- Ulsan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hypertensive patients (systolic blood pressure >140mmHg or diastolic blood pressure >90mmHg) or medically treated hypertension with normal blood pressure who undergo coronary angiography with clinical indications
- 18 < Age < 85
- Patient who has received informed consent
- at least one deferred coronary lesion with 1) visually-estimated angiographic %diameter stenosis 20-50% or 2) %diameter stenosis >50% without any evidence of inducible ischemia (FFR ≥ 0.8 or negative perfusion defect on thallium scan or negative treadmill test)
Exclusion Criteria:
- Planned cardiac surgery (e.g., CABG, valve repair or replacement, or aneurysmectomy) or planned major non-cardiac surgery within the study period
- Planned performance of PCI or CABG in the target vessel or its branches containing the index
- Evidence of congestive heart failure, or left ventricular ejection fraction < 40%
- Stroke or resuscitated sudden death in the past 6 months
- Chronic disease requiring treatment with oral, intravenous, or intra-articular corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible)
- A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer
- Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study
- Significant renal disease manifested by serum creatinine > 1.5 mg/dL
- Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST > 3 times upper limit of normal)
- Active hepatitis B or C or carrier
- Hypotension (systolic blood pressure <90 mmHg)
- Patients already taking ACE inhibitors or ARBs
- Patients with STEMI requiring primary PCI
- Patients pregnant or breast-feeding or child-bearing potential
- Patients who are lack of intention for effective contraception
- Patients with history of previous enrollment into a clinical trials within 3 months
- Allergic or contraindicated to Angiotensin II antagonists
- History of any arterial bypass or angioplastic intervention involving the target vessel
- Luminal narrowing in the left main > 50% by visual inspection of angiogram
- Visually-estimated angiographic reference segment diameter of <2.75mm or >4.0 mm
- Presence of thrombus or complex plaque morphology in the target vessel that suggests a high likelihood of distal embolism
- Severe tortuosity of the target vessel or any other anatomical reasons that the investigator deems
- Inappropriate for IVUS procedures. Vessel with thrombus (on GS-IVUS), moderate or severe calcification, angulation
- Culprit vessel in AMI
- RWMA (Regional Wall Motion Abnormality) or scar tissue in the territory subtended by the studied lesion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Fimasartan
Initial dose will be started with 60mg per day.
At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
|
60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)
Other Names:
|
|
Placebo Comparator: Placebo
Initial dose will be started with 60mg per day.
At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
|
60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in percent necrotic core (NC) volume of plaque by VH (Virtual Histology) in the "target segment" (within deferred vessel)
Time Frame: baseline and 1 year
|
baseline and 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change of total atheroma volume (TAV) and percent atheroma volume (PAV) of the target segment and the most diseased 10-mm segment (normalized to different segment length) with the largest plaque volume
Time Frame: baseline and 1 year
|
baseline and 1 year
|
|
Percent change in minimal lumen area (MLA) in target segment
Time Frame: baseline and 1 year
|
baseline and 1 year
|
|
Change of absolute area or percentages (%) of each plaque VH composition (fibrotic, fibrofatty, dense calcium, necrotic core) at minimal lumen area (MLA) and largest necrotic core area within the target segment
Time Frame: baseline and 1 year
|
baseline and 1 year
|
|
Change of VH-IVUS (Intra Vascular UltraSound) detected plaque type from baseline
Time Frame: at 1 year
|
at 1 year
|
|
Change of percentage (%) of OCT (Optical Coherence Tomography)-defined TCFA (Thin Cap Fibrotic Atheroma) within the target segment from baseline
Time Frame: at 1 year
|
at 1 year
|
|
Change of composition of OCT-defined fibrous, fibro-calcific, and lipid-rich plaque within the target segment
Time Frame: baseline and 1 year
|
baseline and 1 year
|
|
Change of OCT-defined fibrous cap thickness, the presence of plaque disruption, calcification or intraluminal thrombus within the target segment
Time Frame: baseline and 1 year
|
baseline and 1 year
|
|
Change of FFR in target segment from baseline
Time Frame: at 1 year
|
at 1 year
|
|
systolic and diastolic blood pressure
Time Frame: at 1 year follow-up
|
at 1 year follow-up
|
|
Change in high sensitive CRP (C-Reactive Protein)from baseline
Time Frame: at 1 year
|
at 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CVRF2011-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.